Searcharxiv⌕ Search

arXiv subjects

Mohammadreza Riyazat

Publications and source records attributed to Mohammadreza Riyazat.

2 recordsLinked to original sources

AdaPrivate-TS: Private Thompson Sampling for Contextual Bandits with Privacy Amplification

We present AdaPrivate-TS, a differentially private contextual bandit algorithm that combines Thompson Sampling with batched zCDP composition. Our key insight is that differential privacy noise inflates the posterior covariance in a structured way: adding Gaussian noise $N(0,σ^2 I)$ to $b$ yields sampling covariance $v^2 A^{-1} + σ^2 A^{-2}$, which Thompson Sampling interprets as increased uncertainty rather than pure corruption. Under event-level privacy (protecting individual interactions) with stochastic contexts, we prove that the privacy cost is only $O(\sqrt{d}\,\log T/\sqrtρ)$, logarithmic in $T$, because parallel composition amortizes noise across batches. Additionally, we explore privacy amplification via Poisson subsampling, which can reduce effective noise at stringent privacy budgets. Experiments on synthetic and real-world datasets demonstrate: (1) AdaPrivate-TS achieves 93-99% of non-private performance at $\varepsilon \in [0.5, 5]$, outperforming UCB by 0.5-3.7% and up to 18% with tuned adaptive exploration at extreme $\varepsilon$; (2) privacy amplification provides additional 2-5% gains at low $\varepsilon$; (3) on MovieLens and Jester, AdaPrivate-TS achieves the best overall performance among event-level baselines, dominating at $\varepsilon \geq 2$; (4) under DP-SVD private features, TS's advantage over UCB grows to +11%, confirming noise-as-uncertainty is not limited to reward privacy. We provide rigorous proofs for privacy guarantees under interactive zCDP composition and comprehensive evaluation including convergence curves, 12-seed CIs, and DP-SVD feature ablation.

cs.LG↗

MARD: Mirror-Augmented Reasoning Distillation for Mechanism-Level Drug-Drug Interaction Prediction

Mechanism-level drug-drug interaction (DDI) prediction requires identifying which enzyme or pharmacodynamic axis is implicated, in which direction, and with which evidence -- not merely whether two drugs interact. We introduce a reproducible mechanism-level DDI labelling and evaluation protocol with a structured 7-family/147-subtype taxonomy, leakage-safe cold-split protocols, and auditable reasoning metrics for evaluating pharmacological prediction beyond flat interaction classification. We propose a pipeline that produces a 7B reasoning MARD (Mirror-Augmented Reasoning Distillation), combining three training innovations: a single-token KL divergence on direction tag that ties the model's prediction, per-loss PRM-weighted DPO with programmatic hard negatives, and a leakage-safe mechanism-aware retrieval channel. Process-reward step labels are automatically verifiable against DrugBank-structured fields, requiring no human or LLM judges. On the April-2026 DrugBank release, our MARD-7B is the only system in a 32-system comparison whose accuracy survives drug-pair novelty, beating the best baseline by +13.9 pp and GPT-4o by +6.7 pp at ~1% of frontier API cost. Further analysis reveals an anti-memorisation signature where accuracy improves on rarely seen drugs, suggesting that gain comes from structured pharmacological reasoning rather than drug-frequency memorisation. We release corpus, DDI-PRM, retrieval index, and training code.

cs.CL↗